

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61K 37/02, 31/19, 31/40 A61K 31/57, 31/60	A1	(11) International Publication Number: WO 91/07186 (43) International Publication Date: 30 May 1991 (30.05.91)
(21) International Application Number: PCT/AU90/00558 (22) International Filing Date: 21 November 1990 (21.11.90) (30) Priority data: PJ 7503 21 November 1989 (21.11.89) AU (71) Applicant (for all designated States except US): THE UNIVERSITY OF MELBOURNE [AU/AU]; Grattan Street, Parkville, VIC 3052 (AU). (72) Inventors; and (75) Inventors/Applicants (for US only): HAMILTON, John, Allan [AU/AU]; 18 Charles Street, Kew, VIC 3101 (AU). HART, Prudence, Hamilton [AU/AU]; 28 Avenue Street, Millswood, S.A. 5034 (AU). (74) Agents: STEARNE, Peter, Andrew et al.; Davies & Collison, 1 Little Collins Street, Melbourne, VIC 3000 (AU).		(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US. Published <i>With international search report.</i>
(54) Title: ANTI-INFLAMMATORY COMPOSITIONS AND METHODS (7) Abstract Therapeutic compositions and methods for the treatment of inflammation are disclosed. The compositions comprise at least one anti-inflammatory drug in combination with the lymphokine interleukin-4 (IL-4), which components interact synergistically in the treatment of inflammation. Methods for the treatment of inflammation comprise administering to a subject in need of such treatment an effective amount of at least one anti-inflammatory drug and IL-4.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LI	Liechtenstein	SU	Soviet Union
CI	Côte d'Ivoire	LK	Sri Lanka	TD	Chad
CM	Cameroon	LU	Luxembourg	TC	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

- 1 -

5

10

ANTI-INFLAMMATORY COMPOSITIONS AND METHODS

15

This invention relates to therapeutic compositions and methods for the treatment of inflammation.

Inflammation is associated with many disease states, such as rheumatoid arthritis, psoriasis, asthma and allergies, and it is generally thought to be caused by inflammatory mediators such as interleukin-1 (IL-1), tumour necrosis factor- α (TNF- α), histamine and prostaglandin E₂ (PGE₂).

Therapeutics used for the treatment of inflammation fall into two principle classes, namely glucocorticoids and non-steroidal anti-inflammatory agents. Glucocorticoids (also known as corticosteroids) are among the most potent and widely used anti-inflammatory agents and include naturally occurring corticosteroids such as cortisone and hydrocortisone, and synthetic analogues such as betamethasone, dexamethasone, fluprednisolone, prednisone and paramethasone. Non-steroidal anti-inflammatory agents include aspirin, indomethacin, ibuprofen, phenylbutazone and diflusal.

These prior therapeutic agents are often characterised by adverse side effects such as oedema,

- 2 -

hypertension, osteoporosis, delayed wound healing, increased susceptibility to infection, menorrhagia, liver disfunction, nausea and vomiting.

Interleukin-4 (IL-4), a product of activated T lymphocytes has a variety of stimulatory effects on B cells, T cells and mast cells and may be regarded as a proimmune, proinflammatory molecule. As described in International Patent Application No. WO 87/02990, IL-4 may stimulate mast cells to produce molecules such as histamines and prostaglandins. These agents have been implicated as inflammatory mediators.

To date, conventional compositions and methods for the treatment of inflammation have been associated with significant disadvantageous side effects as detailed above. Accordingly, a need exists for compositions and methods which avoid these disadvantages while providing effective treatment of inflammation.

The present invention solves the problems referred to above by providing therapeutic compositions and methods for treating inflammation. This invention is based on the surprising and unexpected finding that IL-4 and anti-inflammatory agents interact synergistically in the treatment of inflammation, that is, IL-4 potentiates the activity of steroidal and non-steroidal anti-inflammatory drugs. As a consequence, significantly less anti-inflammatory drug may be required in the treatment of inflammation, with a reduction in attendant side effects which typically characterise anti-inflammatory treatments.

According to one aspect of the present invention there is provided a composition for the treatment of inflammation which comprises:

- (a) one or more anti-inflammatory drugs; and
- (b) IL-4;

optionally in the presence of one or more pharmaceutically acceptable carriers or excipients.

- 3 -

As has been previously stated in this specification, anti-inflammatory drugs fall into the categories of glucocorticoids or steroidal anti-inflammatory agents, and non-steroidal anti-inflammatory agents. Any

5 steroidal anti-inflammatory agent may be utilized in the present invention. For example, steroidal anti-inflammatory drugs may be selected from cortisone, betamethasone, dexamethasone, fluprednisolone, hydrocortisone, methylprednisolone, paramethasone,

10 prednisolone, prednisone and triamcinolone. Any non-steroidal anti-inflammatory drug may also be utilized in the invention. For example, non-steroidal anti-inflammatory drugs may be selected from aspirin, indomethacin, ibuprofen, phenylbutasone and diflusal.

15 Compositions may contain a combination of steroidal anti-inflammatory agents, non-steroidal anti-inflammatory agents, or both steroidal and non-steroidal anti-inflammatory agents.

Reference to IL-4 is to be taken as reference to

20 principally the human lymphokine IL-4, as described, for example, in International Patent Application No. WO 87/02990 which is incorporated herein in its entirety by reference. Notwithstanding the above definition, IL-4 also refers to animal IL-4, as produced for example by

25 mice, rats, horses, cats, dogs and sheep. The definition IL-4 includes all proteins, polypeptides and peptides which are natural or recombinant IL-4's or derivatives thereof having IL-4 activity which are characterised in having a potentiating activity on anti-inflammatory drugs

30 in the treatment of inflammation. IL-4 derivatives are generally substitution, insertion or deletion variants of IL-4, wherein one or more amino acids are substituted, inserted or deleted into or from the "native" IL-4 amino acid sequence. The IL-4's used in the processes and

35 compositions of this invention may be produced by purification from natural sources using conventional

- 4 -

techniques or may be produced by recombinant DNA methodology. Generally IL-4 used in this invention is homogenous or substantially homogeneous, that is, is at least 95% and more preferably 99% pure as ascertained by analytical techniques such as polyacrylamide gel electrophoresis (PAGE) and high performance liquid chromatography (HPLC). For example, IL-4 may be produced according to the teachings of WO 87/02990 which, as mentioned previously, is incorporated herein by reference.

IL-4 and anti-inflammatory drugs, particularly steroidal antiinflammatory drugs, interact synergistically over a wide range of concentrations of both components, ranging from equimolar amounts of IL-4 to steroid, to excess of steroid or excess of IL-4. Without limiting the invention in any way, the molar excess of anti-inflammatory agent over IL-4 in a therapeutic composition may for example be between $10^{0.5}$ to 10^6 .

In accordance with a further aspect of the present invention there is provided a method for the treatment of inflammation which comprises administering to a subject in need of such treatment a composition comprising a therapeutically effective amount of:

- (i) one or more anti-inflammatory agents; and
 - (ii) a synergistic amount of IL-4;
- optionally in the presence of one or more pharmaceutically acceptable carriers or excipients.

The pharmaceutical composition may be administered in a convenient manner such as by the oral, intravenous, intramuscular, subcutaneous, intraperitoneal, intranasal, intradermal or suppository routes.

The composition also may be administered to a human or animal subject by continuous infusion over a predetermined time period, for example, for 30 minutes to 24 hours. Administration may be by way of an intravenous

- 5 -

catheter connected to an appropriate pump, or by gravity feed.

The amounts of and dosage regimes of IL-4 and anti-inflammatory agents which are administered to a subject will depend on a number of factors such as the mode of administration, the nature of the condition being treated, the body weight of the subject being treated, and the judgement of the prescribing physician or veterinarian. Generally speaking, the anti-inflammatory agent and IL-4 may be administered in a combined amount between 0.1µg to 2000mg per kilogram of body weight per day. The quantity of the two components in a unit dosage such as a tablet or capsule may vary from about 0.1µg to 100 mg, and the molar excess of anti-inflammatory agent(s) over IL-4 may be in the range $10^{0.5}$ to 10^4 .

IL-4 may be coated by, or administered with, a material to prevent its inactivation. For example, the active material may be administered in an adjuvant, co-administered with enzyme inhibitors or in liposomes. Adjuvants contemplated herein include resorcinols, non-ionic surfactants such as polyoxyethylene oleyl ether and n-hexadecyl polyethylene ether. Enzyme inhibitors include pancreatic trypsin inhibitor, diisopropylfluorophosphate (DFP) and trasylol. Liposomes include water-in-oil-in-water P40 emulsions as well as conventional liposomes.

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion

- 6 -

medium containing, for example, sterile water, ethanol, polyol (for example, glycerol, propylene glycol and liquid polyethylene glycol and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of a dispersion, and the use of surfactants. The preventions of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminium monostearate and gelatin.

Sterile injectable solutions are prepared by incorporating the active material in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredient into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze-drying technique which yield a powder of the active ingredient plus any additional desired ingredient from previously sterile-filtered solution thereof.

When IL-4 is suitably protected as described above, the active compound may be orally administered, for example, with an inert diluent or with an edible carrier, or it may be enclosed in hard or soft shell gelatin

- 7 -

capsule, or it may be compressed into tablets, or it may be incorporated directly with the food of the diet. For oral therapeutic administration, the active material may be incorporated with excipients and used in the form of
5 ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.

The tablets, troches, pills, capsules and the like may also contain the following: a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients
10 such as dicalcium phosphate; and disintegrating agents such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin may be added or a flavouring agent such as peppermint,
15 oil of wintergreen, or cherry flavouring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the
20 dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar or both. A syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavouring such as cherry or
25 orange flavour. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, the active material may be incorporated into sustained-release preparations and formulations.

30 As used herein, the terms "pharmaceutically acceptable carrier" and "excipient" include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like described above. The use of such
35 carriers and excipients is well known in the art, see for example, Remington's Pharmaceutical Science and U.S.

- 8 -

Pharmacopeia (1984); Mack Publishing Company, Easton, PA.

IL-4 and steroidal or non-steroidal anti-inflammatory drugs may be administered to a human patient or animal at the same time, or with a time interval
5 between dosage application of each component. This time interval may range from a few seconds to several hours, and may extend from 12 to 24 hours. Therefore, according to a further aspect of this invention there is provided a method for the treatment of inflammation which comprises
10 administering IL-4 and steroidal or non-steroidal drugs to a subject in need of such treatment.

By the present invention, the treatment of inflammation using steroid therapy may be supplemented with low amounts of IL-4 permitting the use of less
15 steroid with concomitant reduction in side effects. This is a result of the synergistic interaction between IL-4 and steroid anti-inflammatory agents such that lesser amounts of steroid, such as 5 to 20 fold less, would be required for anti-inflammatory action.

20 As previously mentioned, IL-4 also potentiates the anti-inflammatory action of non-steroidal anti-inflammatory drugs. The biological mechanisms which underlies the potentiation of anti-inflammatory drug action with IL-4 are unclear. Without wishing to limit
25 the invention in any way, insofar as non-steroidal anti-inflammatory drugs are concerned, it is believed that both IL-4 and the non-steroidal agents inhibit the production of cyclooxygenase products such as prostaglandins. In contrast to non-steroidal agents, IL-
30 4 appears to inhibit the production of other inflammatory mediators such as TNF and IL-1. However, why the combined effects of these agents should be greater than that of each anti-inflammatory agent is uncertain. The mechanism behind the potentiation of steroidal action
35 with IL-4 is also uncertain.

In a still further aspect of this invention, there

- 9 -

is provided a method for the treatment of inflammation or other disorders usually treated with steroids, which method comprises administering to a subject in need of such treatment a therapeutically effective amount of
5 interleukin-4 (IL-4).

This aspect of the invention is based on the finding that IL-4 may act as a steroid replacement. Particularly, the aforementioned compound acts to decrease the production of inflammatory mediators such as
10 IL-1, IL-6, tumour necrosis factor- α (TNF- α), prostaglandin E₂ (PGE₂) and colony stimulating factors (GM-CSF and G-CSF).

The invention will now be described with reference to the following non-limiting Figures and Example. The
15 Examples show results on the production of inflammatory mediators, such as PGE₂, TNF- α and IL-1 β by activated monocytes in culture, after stimulation with lypopolysaccharide (LPS) and IFN- γ in the presence of anti-inflammatory agents, IL-4, or combinations thereof,
20 and clearly depict the synergy between IL-4 and anti-inflammatory agents in suppressing the production of anti-inflammatory mediators. This model system provides direct support for the in-vivo use of IL-4/anti-inflammatory drug combinations in the treatment of
25 inflammation, and for the view that lower amounts of anti-inflammatory drugs would be required for effective therapy when they are administered in concert with IL-4.

The Figures of this application show the following:

Figure 1 shows the effects of IL-4 and Dex on the
30 immunoreactive IL-1 β levels of activated human monocytes from a representative donor. Monocytes are cultured for 18 h with LPS and IFN- γ , together with Dex and IL-4 as indicated. IL-1 β levels were assayed by ELISA. The mean level \pm SEM for supernatants from triplicate cultures is
35 shown; for many values the SEM was too small to be diagrammatically represented;

- 10 -

Figure 2 shows the effects of IL-4 and Dex on the TNF α activities of activated human monocytes. TNF α activities were measured with actinomycin D-treated L929 target cells. Mean activities \pm SEM (n=3) were measured
5 in the same supernatants for which IL-1 β levels are shown in Figure 1; for some measurements the SEM was too small to be diagrammatically represented;

Figure 3 shows the effects of IL-4 and Dex on the PGE₂ levels of activated human monocytes. Levels of PGE₂
10 were determined by immunoassay. Mean levels \pm SEM (n=3) were measured in the same supernatants for which IL-1 β levels and TNF α activities are shown in Figures 1 and 2 respectively; for some measurements the SEM was too small to be diagrammatically represented;

15 Figure 4 shows the opposing effects of IL-4 and Dex on the PA activities of activated monocytes from a representative donor. PA activities were measured (A) in the supernatants of monocytes co-incubated with Dex alone (activity range 0.04-0.14 IU/10⁶ cells), and (B) in the
20 supernatants of monocytes co-incubated with both IL-4 and Dex (activity range 0-2.0 IU/10⁶ cells). PA activities were assayed as described herein; greater than 95% of activity measured was plasminogen-dependent. Mean activities \pm SEM for triplicate cultures are shown; for
25 some measurements the SEM was too small to be diagrammatically represented;

Figure 5 shows the effect of IL-4 and Indomethacin on (A) immunoreactive IL-1 β , and (B) immunoreactive TNF α levels for stimulated human monocytes. Monocytes from a
30 different donor for whom results are shown in Figures 1 to 4 were isolated, cultured and stimulated as described; IL-1 β was measured by ELISA and TNF α by radioimmunoassay. Mean levels \pm SEM for triplicate cultures are shown; however, for some measurements, the SEM was too small to
35 be diagrammatically represented.

- 11 -

ABBREVIATIONS:

- DEX - dexamethasone
IFN - interferon
IL - interleukin
5 LPS - lipopolysaccharide
PA - plasminogen activator
TNF - tumour necrosis factor
FCS - fetal calf serum
Mab - monoclonal antibody

10

EXAMPLE 1

- Assays for IL-1, TNF α , PGE₂ and plasminogen activator were carried out according to the methods of Hart et al. (Proc. Natl. Acad. Sci. U.S.A. 86: 3803; Blood 74: 551; 15 Immunology 66: 376; J. Immunol. 141: 1516) details of which are incorporated herein by reference in their entirety.

Monocyte Isolation and Culture:

- Monocytes ($\geq 95\%$ purity) were isolated from 20 peripheral venous blood by countercurrent centrifugal elutriation and cultured ($0.8-1.0 \times 10^6/\text{ml}$) for 18 h in α -modified Eagle's medium containing 1% FCS. All monocytes were stimulated with LPS from Escherichia coli 0111:B4 (100 ng/ml, Difco Laboratories Inc., Detroit, MI) and 25 human rIFN- γ (100 U/ml; Dr. E. Hochuli, Hoffmann-La Roche, Basel, Switzerland). Dex (Sigma Chemical Co., St. Louis, MO) was added at $0-10^{-7}\text{M}$; IL-4 (Ms. A. Van Kimmenade, DNAX, Palo Alto, CA.) was added at $0-2.5 \text{ U/ml}$.

Assays:

- 30 IL-1 β levels were measured by an ELISA using mAb to IL-1 β from Dr. A.C. Allison, Syntex, Palo Alto, CA. A murine thymocyte comitogenesis assay was used to measure IL-1 bioactivity.

- TNF α activities were measured with actinomycin D- 35 treated L929 target cells and using a human rTNF α standard (Dr. G.R. Adolf, Ernst-Boehringer Institut,

- 12 -

Vienna, Austria). Immunoreactive TNF α was measured by radioimmunoassay.

PGE₂ (≥ 0.03 ng/ml) was determined by immunoassay using competitive adsorption to dextran-coated charcoal :
5 (PGE₂ ³H/RIA Kit, Seragen, Boston, MA).

Plasminogen activator (PA) activity was assayed by measurement of ¹²⁵I-fibrin degradation products and expressed according to the activity of a tissue-type PA (t-PA) standard (National Institute for Biological
10 Standards and Control, London).

Experimental Results:

IL-1: The changes of IL-1 β protein due to addition of IL-4 and Dex to monocytes stimulated with LPS and IFN- γ are shown in Figure 1. IL-4 concentrations as low as
15 0.05 U/ml potentiated the action of Dex ($1-5 \times 10^{-9}$ M). When the mean levels for stimulated monocytes from four donors were compared, Dex (10^{-7} M) reduced the IL-1 β levels from 11.8 ± 5.6 ng/ 10^6 cells (means \pm SEM) to 2.5 ± 1.1 ng/ 10^6 cells, while for Dex (5×10^{-9} M) with IL-4 (0.5
20 U/ml) the IL-1 β levels were reduced to 1.0 ± 0.4 ng/ 10^6 cells. Thus, 20 fold less DEX, in the presence of IL-4 showed significant inhibition of inflammatory mediators.

TNF α : When TNF α activities were quantified, 5×10^{-9} M Dex in the presence of 2.5 U IL-4/ml was as effective as 10^{-7} M and 2×10^{-8} M Dex (Figure 2). When the mean activities
25 from triplicate cultures of monocytes isolated from four donors were compared, the TNF α activities induced by LPS with IFN- γ (478 ± 188 U/ 10^6 cells, mean \pm SEM) were reduced by Dex (10^{-7} M) to 14 ± 9 U/ 10^6 cells, whereas Dex
30 (5×10^{-9} M) together with IL-4 (2.5 U/ml) reduced TNF α activities to 68 ± 40 U/ 10^6 cells. Similar findings (data not shown) were obtained using an immunoassay for TNF α .

PGE₂: For monocyte PGE₂ production, similar results were obtained (Figure 3). For four donors, LPS with IFN- γ
35 induced 7.7 ± 1.0 ng PGE₂/ 10^6 cells (mean \pm SEM). Dex (10^{-7} M) lowered PGE₂ levels to 0.3 ± 0.1 ng/ 10^6 cells,

- 13 -

while Dex (5×10^{-9} M) with IL-4 (0.5 U/ml) reduced PGE₂ levels to 0.4 ± 0.2 ng/ 10^6 cells.

Tissue Plasminogen Activator: Dex and IL-4 do not always potentiate the action of each other on monocyte product synthesis. PA activity was measured in the same supernatants which were used to obtain the data presented in Figures 1 to 3. Whereas increasing concentrations of Dex suppressed the action of LPS with IFN- γ for enhanced PA activity (Figure 4A), increasing concentrations of IL-4 potentiated it and opposed the suppressive effects of Dex (Figure 4B). This observation was confirmed in four donors. We also confirmed that detectable PA activity in the monocyte supernatants was t-PA and not urokinase-type PA (u-PA) by SDS-PAGE zymography and by antibody blocking and depletion of t-PA activity.

IL-4 and Non-Steroidal Anti-Inflammatory Agents:

We have found previously that endogenous cyclooxygenase products inhibit partially the production of IL-1 and TNF α by stimulated human monocytes (Hart, et al., Immunology 66: 736). Thus, non-steroidal anti-inflammatory drugs which suppress cyclooxygenase product formation, paradoxically enhance the levels of these pro-inflammatory mediators. Figures 5A and 5B confirm these observations for monocytes stimulated by LPS and IFN- γ , $\geq 10^{-6}$ M indomethacin completely suppressed PGE₂ production (data not shown). On addition of IL-4 at 0.1 and 2.5 U/ml to non-indomethacin-treated cells, the PGE₂ levels induced by LPS with IFN- γ fell from 14.7 ng/ 10^6 cells to 9.5 and 1.4 ng/ 10^6 cells, respectively, when the values were averaged for triplicate cultures of monocytes from the two donors studied. Thus, in response to 2.5 U IL-4/ml when minimal PGE₂ production occurred, the increases in IL-1 β and TNF α levels measured in response to indomethacin were removed (Figures 5A and 5B).

These results show that when low concentrations of IL-4 and Dex are added together to cultures of activated

- 14 -

monocytes, the resultant inhibition of the synthesis of IL-1, TNF α and PGE $_2$ is significantly greater than if either agent were added alone. To what extent the biochemical mechanisms involved in the inhibitory actions of IL-4 on monocyte product synthesis are similar to those involved in glucocorticoid-mediated regulation is unclear. Given the wide-ranging but often adverse effects of glucocorticoid treatment, it is encouraging that IL-4 has at least one different action to Dex on the monocyte, viz. the opposite effect on the production of the fibrinolytic enzyme, t-PA (Figure 4). This t-PA-inducing property of IL-4 may further support its use with glucocorticoids because there is evidence that fibrin formed as a result of lymphokine activation of monocyte/macrophage procoagulant activity, may play a role in immune reactions associated with disease such as rheumatoid arthritis, glomerular nephritis and granulomatous disease.

Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications which fall within its spirit and scope. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps of features.

- 15 -

CLAIMS:

1. A composition for the treatment of inflammation which comprises a therapeutically effective amount of at least one anti-inflammatory drug and IL-4.

2. A composition according to claim 1 wherein said anti-inflammatory drug is a steroidal anti-inflammatory.

3. A composition according to claim 2 wherein said steroidal anti-inflammatory is selected from cortisone, betamethasone, dexamethasone, fluprednisolone, hydrocortisone, methylprednisolone, paramethasone, prednisolone, prednisone and triamcinolone.

4. A composition according to claim 1 wherein said anti-inflammatory drug is a non-steroidal anti-inflammatory.

5. A composition according to claim 4, wherein said non-steroidal anti-inflammatory is selected from aspirin, indomethacin, ibuprofen, phenylbutasone and diflusal.

6. A composition according to claim 1 which comprises a steroidal anti-inflammatory, a non-steroidal anti-inflammatory and IL-4.

7. A composition according to claim 1 wherein said IL-4 is recombinant human IL-4.

8. A composition according to claim 2 wherein said IL-4 is non-recombinant human IL-4.

9. A composition according to claim 1 wherein the IL-4 is a compound having IL-4 activity.

- 16 -

10. A composition according to claim 1 which additionally comprises one or more pharmaceutically acceptable carriers.

11. A composition according to any one of claims 1 to 10 wherein the anti-inflammatory agent is in molar excess over the IL-4 in the range $10^{0.5}$ to 10^4 .

12. A method for the treatment of inflammation which comprises administering to a subject in need of such treatment a composition as claimed in any one of claims 1 to 11.

13. A method according to claim 12 wherein the inflammation is associated with rheumatoid arthritis, psoriasis, asthma or allergy.

14. A method according to claim 12 wherein the anti-inflammatory agent and IL-4 are administered in a combined amount between 0.1 μ g to 2000 mg per kg of body weight of the subject.

15. A method for the treatment of inflammation which comprises administering to a subject in need of such treatment a therapeutically effective amount of IL-4.




FIGURE 1

SUBSTITUTE SHEET

2/7




FIGURE 2

SUBSTITUTE SHEET

3/7





FIGURE 3

SUBSTITUTE SHEET

4/7


FIGURE 4



SUBSTITUTE SHEET

5/7


FIGURE 4



SUBSTITUTE SHEET


6/7

FIGURE 5



7/7


FIGURE 5



SUBSTITUTE SHEET

INTERNATIONAL SEARCH REPORT

International Application No. **PCT/AU 90/00558**

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) 6				
According to International Patent Classification (IPC) or to both National Classification and IPC				
Int. Cl. ⁵ A61K 37/02, 31/19, 31/40, 31/57, 31/60				
II. FIELDS SEARCHED				
Minimum Documentation Searched 7				
Classification System	Classification Symbols			
IPC ⁵	A61K 37/02			
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched 8				
III. DOCUMENTS CONSIDERED TO BE RELEVANT 9				
Category*	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages 12	Relevant to Claim No 13		
P,Y	AU,A. 44113/89 (COSMAN, D.J. et al) 17 May 1990 (17.05.90)	(1-15)		
Y	AU,A. 67334/87 (LEE, F. et al) 21 May 1987 (21.05.87)	(1-15)		
X	Proc. Natl. Acad. Sci U.S.A. Vol.86 pp 3803-3807, Published	(15)		
Y	May 1989. "Potential antiinflammatory effects of interleukin 4 : Suppression of human monocyte tumor necrosis factor α , interleukin 1, and prostaglandin E2 (HART, P.H. et al), Page 3807	(1-14)		
P,Y	AU,A. 41563/89 (SNICK, J.V. et al) 22 March 1990 (22.03.90)	(1-15)		
<p>* Special categories of cited documents: 10</p> <table style="width: 100%;"> <tr> <td style="width: 50%;"> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </td> <td style="width: 50%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"Z" document member of the same patent family</p> </td> </tr> </table>			<p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"Z" document member of the same patent family</p>
<p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"Z" document member of the same patent family</p>			
IV. CERTIFICATION				
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report			
21 February 1990 (21.02.90)	5 March 1991			
International Searching Authority	Signature of Authorized Officer			
Australian Patent Office	 J.P. PULVIRENTI			

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON
INTERNATIONAL APPLICATION NO. PCT/AU 90/00558

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Members			
AU 41563/89	DK 4588/89	EP 361284	IL 91691		
	JP 3004796				
AU 44113/89	IL 91705	EP 367566	WO 9005183		
	JP 2215385	ZA 8908014			
AU 67334/87	CN 86108579	DK 3710/87	EP 230107		
	EP 249613	FI 873141	HU 43630		
	IL 80678	NO 872988	PT 83761		
	WO 8702990				

END OF ANNEX

